References
- Girling D J. Adverse reactions to rifampicin in antituberculosis regimens. J Antimicrob Chemother 1977; 3: 115–132
- Grosset J, Leventis S. Adverse effects of rifampicin. Rev Infect Dis 1983; 5: S440–S446, Suppl. 3
- Sister Mary Aquinas, Allan W GL, Horsfall P AL, Jenkins P K, Wong Hung-Yan, Girling D, Tall R, Fox W. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J 1972; 765–771
- Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council. A controlled trial of daily and intermittent rifampicin plus ethambutol in the re-treatment of patients with pulmonary tuberculosis: Results up to 30 months. Tubercle 1975; 56: 179–189
- Andrews R H, Jenkins P A, Marks J, Pines A, Selkon J B, Somner A R. Treatment of isoniazid resistant pulmonary tuberculosis with ethambutol, rifampicin and capreomycin. Tubercle 1974; 55: 105–113
- Lees A W, Allan G W, Smith J, Tyrell W F, Fallen R J. Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52: 182–190
- Davies A J, Lewis D A. Rifampicin in non-tuberculous infections. Br Med J 1984; 289: 3–4
- Sande M A. The use of rifampicin in the treatment of non-tuberculous infections. Rev Infect Dis 1983; 5: S399–S401, Suppl 3